Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works

Neoantigens in cancer immunotherapy

Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783 · see citing works

Innate and adaptive immune cells in the tumor microenvironment

Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148 · see citing works

The complexity of NF-κB signaling in inflammation and cancer

Hoesel, B., & Schmid, J. A. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-86 · Cited by 3,194 · see citing works

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830 · see citing works

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P. L., Mackiewicz, A. A., Stroyakovskiy, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,698 · see citing works

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · see citing works

IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer

Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433 · see citing works

The immune contexture in cancer prognosis and treatment

Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263 · see citing works

Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma

Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V. G., Liszkay, G., Maio, M., Mandalà, M., Демидов, Л. В., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,062 · see citing works

Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment

Yu, H., Kortylewski, M., & Pardoll, D. M. (2006) · Nature reviews. Immunology · doi:10.1038/nri1995 · Cited by 1,809 · see citing works

Up-Regulation of PD-L1, IDO, and T _regs in the Melanoma Tumor Microenvironment Is Driven by CD8 ⁺ T Cells

Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677 · see citing works

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma

Long, G. V., Hauschild, A., Santinami, M., Atkinson, V. G., Mandalà, M., Chiarion‐Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708539 · Cited by 1,510 · see citing works

PD-L1 Expression in Triple-Negative Breast Cancer

Mittendorf, E. A., Philips, A. V., Meric‐Bernstam, F., Qiao, N., Wu, Y., Harrington, S. M., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akçakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,394 · see citing works

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

Planchard, D., Smit, E. F., Groen, H. J. M., Mazières, J., Besse, B., Helland, Å., Giannone, V., D'amelio, A. M., Zhang, P., Mookerjee, B., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30679-4 · Cited by 1,360 · see citing works

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2006) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,341 · see citing works

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

Akbay, E. A., Koyama, S., Carretero, J., Altabef, A. B., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,237 · see citing works

Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells

Fuertes, M. B., Kacha, A. K., Kline, J., Woo, S.-R., Kranz, D. M., Murphy, K. M., & Gajewski, T. F. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101159 · Cited by 1,192 · see citing works

Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

Wang, T., Niu, G., Kortylewski, M., Burdelya, L. G., Shain, K. H., Zhang, S., Bhattacharya, R., Gabrilovich, D. I., Heller, R. F., Coppola, D., et al. (2003) · Nature Medicine · doi:10.1038/nm976 · Cited by 1,159 · see citing works

The lung microenvironment: an important regulator of tumour growth and metastasis

Altorki, N. K., Markowitz, G. J., Gao, D., Port, J. L., Saxena, A., Stiles, B. M., McGraw, T. E., & Mittal, V. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0081-9 · Cited by 1,147 · see citing works

Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment

Harlin, H., Meng, Y., Peterson, A. C., Zha, Y., Tretiakova, M., Slingluff, C., McKee, M., & Gajewski, T. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2281 · Cited by 1,121 · see citing works

Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?

Coussens, L. M., Zitvogel, L., & Palucka, A. K. (2013) · Science · doi:10.1126/science.1232227 · Cited by 1,070 · see citing works

Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity

Kortylewski, M., Kujawski, M., Wang, T., Sheng, W., Zhang, S., Pilon‐Thomas, S., Niu, G., Kay, H. D., Mulé, J. J., Kerr, W. G., et al. (2005) · Nature Medicine · doi:10.1038/nm1325 · Cited by 1,026 · see citing works

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Ascierto, P. A., McArthur, G. A., Dréno, B., Atkinson, V. G., Liszkay, G., Giacomo, A. M. D., Mandalà, M., Демидов, Л. В., Stroyakovskiy, D., Thomas, L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30122-x · Cited by 1,022 · see citing works

Tumor-associated macrophages: from basic research to clinical application

Yang, L., & Zhang, Y. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0430-2 · Cited by 847 · see citing works

Next generation of immune checkpoint therapy in cancer: new developments and challenges

Marin-Acevedo, J. A., Dholaria, B., Soyano, A. E., Knutson, K. L., Chumsri, S., & Lou, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0582-8 · Cited by 802 · see citing works

Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.

Lastwika, K. J., Wilson, W., Li, Q. K., Norris, J., Xu, H., Ghazarian, S. R., Kitagawa, H., Kawabata, S., Taube, J. M., Yao, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-3362 · Cited by 785 · see citing works

Wnt/beta-catenin pathway: modulating anticancer immune response

Pai, S. G., Carneiro, B. A., Mota, J. M., da Costa, R. B., Leite, C. A., Barroso‐Sousa, R., Kaplan, J. B., Chae, Y. K., & Giles, F. J. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0471-6 · Cited by 712 · see citing works

The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells

Sumimoto, H., Imabayashi, F., Iwata, T., & Kawakami, Y. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051848 · Cited by 696 · see citing works

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

Long, G. V., Flaherty, K. T., Stroyakovskiy, D., Gogas, H. J., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx176 · Cited by 672 · see citing works

Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression

Bassères, D. S. D. S., & Baldwin, A. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209942 · Cited by 666 · see citing works

Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA

Coelho, M. A., de Carné Trécesson, S., Rana, S., Zecchin, D., Moore, C., Molina-Arcas, M., East, P., Spencer-Dene, B., Nye, E., Barnouin, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.016 · Cited by 653 · see citing works

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

Azuma, K., Ota, K., Kawahara, A., Hattori, S., Iwama, E., Harada, T., Matsumoto, K., Takayama, K., Takamori, S., Kage, M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu242 · Cited by 643 · see citing works

STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment

Koyama, S., Akbay, E. A., Li, Y. Y., Aref, A. R., Skoulidis, F., Herter-Sprie, G. S., Buczkowski, K. A., Liu, Y., Awad, M. M., Denning, W. L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1439 · Cited by 640 · see citing works

Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression

Wang, G., Lü, X., Dey, P., Deng, P., Wu, C.-C., Jiang, S., Fang, Z., Zhao, K., Konaparthi, R., Hua, S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0224 · Cited by 556 · see citing works

Myc Cooperates with Ras by Programming Inflammation and Immune Suppression

Kortlever, R. M., Sodir, N. M., Wilson, C. H., Burkhart, D. L., Pellegrinet, L., Brown Swigart, L., Littlewood, T. D., & Evan, G. I. (2017) · Cell · doi:10.1016/j.cell.2017.11.013 · Cited by 553 · see citing works

Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer

Prendergast, G. C., Smith, C., Thomas, S., Mandik‐Nayak, L., Laury‐Kleintop, L. D., Metz, R. A., & Muller, A. J. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1549-4 · Cited by 484 · see citing works

Cancer and the gut microbiota: An unexpected link

Zitvogel, L., Galluzzi, L., Viaud, S., Vétizou, M., Daillère, R., Merad, M., & Kroemer, G. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010473 · Cited by 465 · see citing works

The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity

Moroishi, T., Hayashi, T., Pan, W., Fujita, Y., Holt, M. V., Qin, J., Carson, D. A., & Guan, K. (2016) · Cell · doi:10.1016/j.cell.2016.11.005 · Cited by 435 · see citing works

Enhancing Chemotherapy Efficacy in Pten-Deficient Prostate Tumors by Activating the Senescence-Associated Antitumor Immunity

Toso, A., Revandkar, A., Di Mitri, D., Guccini, I., Proietti, M., Sarti, M., Pinton, S., Zhang, J., Kalathur, M., Civenni, G., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.044 · Cited by 418 · cited 1× · see citing works

p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells

Iannello, A., Thompson, T. W., Ardolino, M., Lowe, S. W., & Raulet, D. H. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130783 · Cited by 414 · see citing works

Indoleamine 2,3‐dioxygenase in T‐cell tolerance and tumoral immune escape

Katz, J. B., Muller, A. J., & Prendergast, G. C. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00610.x · Cited by 399 · see citing works

Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression

Xu, C., Brainson, C. F., Koyama, S., Wu, H., Zhao, Y., Chen, Z., Herter-Sprie, G. S., Akbay, E. A., Tchaicha, J. H., Altabef, A. B., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.033 · Cited by 394 · see citing works

The role of stromal cancer-associated fibroblasts in pancreatic cancer

Ahrens, D. V., Bhagat, T. D., Nagrath, D., Maitra, A., & Verma, A. K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0448-5 · Cited by 389 · see citing works

Receptor Tyrosine Kinases and TLR/IL1Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and Progression

Schmid, M. C., Avraamides, C. J., Dippold, H. C., Franco, I., Foubert, P., Ellies, L. G., Acevedo, L. M., Manglicmot, J. R. E., Song, X., Wrasidlo, W., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.016 · Cited by 378 · see citing works

The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer

Zhang, N., Zeng, Y., Du, W., Zhu, J., Shen, D., Liu, Z., & Huang, J.-A. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3632 · Cited by 362 · see citing works

Long-Term Cytomegalovirus Infection Leads to Significant Changes in the Composition of the CD8+T-Cell Repertoire, Which May Be the Basis for an Imbalance in the Cytokine Production Profile in Elderly Persons

Almanzar, G., Schwaiger, S., Jenewein, B., Keller, M., Herndler‐Brandstetter, D., Würzner, R., Schönitzer, D., & Grubeck‐Loebenstein, B. (2005) · Journal of Virology · doi:10.1128/jvi.79.6.3675-3683.2005 · Cited by 356 · see citing works

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

Ascierto, P. A., Ferrucci, P. F., Fisher, R. A., Vecchio, M. D., Atkinson, V. G., Schmidt, H., Schachter, J., Queirolo, P., Long, G. V., Giacomo, A. M. D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0448-9 · Cited by 326 · see citing works

First-in-human phase I study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies

Beatty, G. L., O'Dwyer, P. J., Clark, J., Shi, J. G., Bowman, K. J., Scherle, P. A., Newton, R. C., Schaub, R., Maleski, J., Leopold, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2272 · Cited by 314 · see citing works

The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1

van Rensburg, H. J. J., Azad, T., Ling, M., Hao, Y., Snetsinger, B., Khanal, P., Minassian, L. M., Graham, C. H., Rauh, M. J., & Yang, X. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3139 · Cited by 307 · see citing works

Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer

Concha‐Benavente, F., Srivastava, R. M., Trivedi, S., Lei, Y. L., Chandran, U. R., Seethala, R. R., Freeman, G. J., & Ferris, R. L. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-2001 · Cited by 306 · see citing works

Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma

Khalili, J. S., Liu, S., Rodríguez-Cruz, T., Whittington, M., Wardell, S., Liu, C., Zhang, M., Cooper, Z. A., Frederick, D. T., Li, Y., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1632 · Cited by 302 · see citing works

Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study

Ribas, A., Gonzalez, R. C., Pavlick, A. C., Hamid, O., Gajewski, T. F., DAUD, A. I., Flaherty, L. E., Logan, T. F., Chmielowski, B., Lewis, K. D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70301-8 · Cited by 300 · see citing works

KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma

Chen, N., Fang, W., Zhong, L., Peng, P., Wang, J., Zhan, J., Hong, S., Huang, J., Liu, L., Sheng, J., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2005-z · Cited by 294 · see citing works

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Horwitz, S. M., Koch, R., Porcu, P., Oki, Y., Moskowitz, A., Perez, M., Myskowski, P., Officer, A., Jaffe, J. D., Morrow, S. N., et al. (2018) · Blood · doi:10.1182/blood-2017-08-802470 · Cited by 290 · see citing works

Glioblastoma Cancer-Initiating Cells Inhibit T-Cell Proliferation and Effector Responses by the Signal Transducers and Activators of Transcription 3 Pathway

Wei, J., Barr, J., Kong, L.-Y., Wang, Y., Wu, A., Sharma, A. K., Gumin, J., Henry, V. K., Colman, H., Priebe, W., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0734 · Cited by 278 · see citing works

Regulation of cell death and autophagy by IKK and NF‐κB: critical mechanisms in immune function and cancer

Baldwin, A. S. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01095.x · Cited by 277 · see citing works

Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy

Glodde, N., Bald, T., Konijnenberg, D., Nakamura, K., O’Donnell, J. S., Szczepanski, S., Brandes, M., Eickhoff, S., Das, I., Shridhar, N., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.09.012 · Cited by 277 · see citing works

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

Jung, K. H., LoRusso, P. M., Burris, H. A., Gordon, M. S., Bang, Y., Hellmann, M. D., Cervantes, A. M. R., de Olza, M. O., Marabelle, A., Hodi, F. S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2740 · Cited by 277 · see citing works

The role of Nuclear Factor-kappa B signaling in human cervical cancer

Tilborghs, S., Corthouts, J., Verhoeven, Y., Ron, D. A., Rolfo, C. D., Trinh, X. B., & van Dam, P. A. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.11.001 · Cited by 271 · see citing works

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial

Grob, J., Amonkar, M. M., Karaszewska, B., Schachter, J., Dummer, R., Mackiewicz, A. A., Stroyakovskiy, D., Drucis, K., Grange, F., Chiarion‐Sileni, V., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00087-x · Cited by 270 · see citing works

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

Flinn, I. W., O'Brien, S. M., Kahl, B. S., Patel, M. R., Oki, Y., Foss, F. M., Porcu, P., Jones, J. A., Burger, J. A., Jain, N., et al. (2017) · Blood · doi:10.1182/blood-2017-05-786566 · Cited by 266 · see citing works

Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward

Li, J., Li, W., Huang, K., Zhang, Y., Kupfer, G. M., & Zhao, Q. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0568-6 · Cited by 245 · see citing works

CAR T‐cell therapy of solid tumors

Yong, C. S. M., Dardalhon, V., Devaud, C., Taylor, N. N., Darcy, P. K., & Kershaw, M. H. (2016) · Immunology and Cell Biology · doi:10.1038/icb.2016.128 · Cited by 221 · see citing works

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Maio, M., Lewis, K., Demidov, L., Mandalà, M., Bondarenko, I., Ascierto, P. A., Herbert, C., Mackiewicz, A. A., Rutkowski, P., Guminski, A. D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30106-2 · Cited by 215 · see citing works

Prognostic significance and mechanism of Treg infiltration in human brain tumors

Jacobs, J. F. M., Idema, A. J. S., Bol, K. F., Grotenhuis, J. A., de Vries, I. J. M., Wesseling, P., & Adema, G. J. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.05.020 · Cited by 212 · see citing works

Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion

Wang, D., Yang, L., Yue, D., Cao, L., Li, L., Wang, D., Ping, Y., Shen, Z., Zheng, Y., Wang, L., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.03.040 · Cited by 183 · see citing works

PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer

Crane, C. A., Panner, A., Murray, J. C., Wilson, S. P., Xu, H., Chen, L., Simko, J. P., Waldman, F. M., Pieper, R. O., & Parsa, A. T. (2009) · Oncogene · doi:10.1038/onc.2008.384 · Cited by 181 · see citing works

Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy

Holtzhausen, A., Zhao, F. L., Evans, K. S., Tsutsui, M., Orabona, C., Tyler, D. S., & Hanks, B. A. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0167 · Cited by 179 · see citing works

IL‐10 derived from M2 macrophage promotes cancer stemness via JAK1/STAT1/NF‐κB/Notch1 pathway in non‐small cell lung cancer

Li, Y., Dong, Y., Li, Y., Wang, D., Liu, S., Wang, D., Gao, Q., Ji, S., Chen, X., Lei, Q., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32151 · Cited by 175 · see citing works

A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors

Soliman, H. H., Jackson, E., Neuger, T., Dees, E. C., Harvey, R. D., Han, H., Ismail-Khan, R., Minton, S., Vahanian, N. N., Link, C., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2357 · Cited by 174 · see citing works

Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis

Hsu, H.-H., Chen, M., Baskaran, R., Lin, Y., Day, C. H., Lin, Y., Tu, C., Padma, V. V., Kuo, W., & Huang, C. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26406 · Cited by 173 · see citing works

Understanding Local Macrophage Phenotypes In Disease: Modulating macrophage function to treat cancer

Bronte, V., & Murray, P. J. (2015) · Nature Medicine · doi:10.1038/nm.3794 · Cited by 172 · see citing works

Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance

Hennequart, M., Pilotte, L., Canè, S., Hoffmann, D., Stroobant, V., Plaen, E. D., & den Eynde, B. J. V. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0400 · Cited by 171 · see citing works

Local activation of p53 in the tumor microenvironment overcomes immune suppression and enhances antitumor immunity

Guo, G., Yu, M., Xiao, W., Celis, E., & Cui, Y. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2832 · Cited by 168 · see citing works

Immune Suppression and Resistance Mediated by Constitutive Activation of Wnt/β-Catenin Signaling in Human Melanoma Cells

Yaguchi, T., Goto, Y., Kido, K., Mochimaru, H., Sakurai, T., Tsukamoto, N., Kudo‐Saito, C., Fujita, T., Sumimoto, H., & Kawakami, Y. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102282 · Cited by 164 · see citing works

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

Nayak-Kapoor, A., Hao, Z., Sadek, R., Dobbins, R., Marshall, L., Vahanian, N. N., Ramsey, W. J., Kennedy, E. P., Mautino, M. R., Link, C. J., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0351-9 · Cited by 163 · see citing works

Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells

Zdanov, S., Mandapathil, M., Eid, R. A., Adamson-Fadeyi, S., Wilson, W., Qian, J., Carnie, A., Tarasova, N. I., Mkrtichyan, M., Berzofsky, J. A., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0241 · Cited by 157 · see citing works

IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression

Zhang, X., Rao, A., Sette, P., Deibert, C., Pomerantz, A., Kim, W. J., Kohanbash, G., Chang, Y., Park, Y., Engh, J. A., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now061 · Cited by 157 · see citing works

Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation

Ai, L., Mu, S., Sun, C., Fan, F., Yan, H., Qin, Y., Cui, G., Wang, Y., Guo, T., Mei, H., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1011-5 · Cited by 147 · see citing works

Tumor-intrinsic oncogene pathways mediating immune avoidance

Spranger, S., & Gajewski, T. F. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1086862 · Cited by 146 · see citing works

A phase I study of indoximod in patients with advanced malignancies

Soliman, H. H., Minton, S. E., Han, H. S., Ismail-Khan, R. R., Neuger, A. M., Khambati, F. A., Noyes, D. R., Lush, R. M., Chiappori, A., Roberts, J. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8216 · Cited by 145 · see citing works

Pten Null Prostate Epithelium Promotes Localized Myeloid-Derived Suppressor Cell Expansion and Immune Suppression during Tumor Initiation and Progression

Garcia, A. J., Ruscetti, M. A., Arenzana, T. L., Tran, L. M., Bianchi-Frias, D., Sybert, E., Priceman, S. J., Wu, L., Nelson, P. S., Smale, S. T., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00090-14 · Cited by 143 · see citing works

NF-κB Hyperactivation in Tumor Tissues Allows Tumor-Selective Reprogramming of the Chemokine Microenvironment to Enhance the Recruitment of Cytolytic T Effector Cells

Muthuswamy, R., Berk, E., Junecko, B. A. F., Zeh, H. J., Zureikat, A. H., Normolle, D. P., Luong, T. M., Reinhart, T. A., Bartlett, D. L., & Kaliński, P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4136 · Cited by 139 · see citing works

Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment

Cui, Y. R., & Guo, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111942 · Cited by 135 · see citing works

Stat3 Activity in Melanoma Cells Affects Migration of Immune Effector Cells and Nitric Oxide-Mediated Antitumor Effects

Burdelya, L., Kujawski, M., Niu, G., Zhong, B., Wang, T., Zhang, S., Kortylewski, M., Shain, K., Kay, H., Djeu, J., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.7.3925 · Cited by 131 · see citing works

The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment

Chang, N., Ahn, S. H., Kong, D., Lee, H. W., & Nam, D. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.01.004 · Cited by 112 · see citing works

Inhibition of both BRAF and MEK in BRAFV600E mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties

Ott, P. A., Henry, T., Baranda, S. J., Frleta, D., Manches, O., Bogunovic, D., & Bhardwaj, N. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1389-z · Cited by 103 · see citing works

Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis

Shabaneh, T. B., Molodtsov, A. K., Steinberg, S. M., Zhang, P., Torres, G. M., Mohamed, G. A., Boni, A., Curiel, T. J., Angeles, C. V., & Turk, M. J. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0365 · Cited by 103 · see citing works

TLR4 Signaling Induces B7-H1 Expression Through MAPK Pathways in Bladder Cancer Cells

Qian, Y., Deng, J., Geng, L., Xie, H., Jiang, G., Zhou, L., Wang, Y., Yin, S., Feng, X., Liu, J., et al. (2008) · Cancer Investigation · doi:10.1080/07357900801941852 · Cited by 101 · see citing works

Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors

Steinberg, S. M., Shabaneh, T. B., Zhang, P., Martyanov, V., Li, Z., Malik, B. T., Wood, T. A., Boni, A., Molodtsov, A. K., Angeles, C. V., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1755 · Cited by 100 · see citing works

A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer

Kristeleit, R. S., Давиденко, І., Shirinkin, V., El-Khouly, F., Bondarenko, I., Goodheart, M. J., Горбунова, В. А., Penning, C. A., Shi, J. G., Liu, X., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.07.005 · Cited by 100 · see citing works

Activation of Akt as a Mechanism for Tumor Immune Evasion

Noh, K. H., Kang, T. H., Kim, J. H., Pai, S. I., Lin, K. Y., Hung, C., Wu, T. ‐., & Kim, T. W. (2008) · Molecular Therapy · doi:10.1038/mt.2008.255 · Cited by 97 · see citing works

An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma

Sun, H., Yang, W., Tian, Y., Zeng, X., Zhou, J., Mok, M. T. S., Tang, W., Feng, Y., Xu, L., Chan, A. W. H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07402-8 · Cited by 93 · see citing works

CD200R signaling in tumor tolerance and inflammation: A tricky balance

Rygiel, T. P., & Meyaard, L. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.01.002 · Cited by 88 · see citing works

Tryptophan Catabolism and Cancer Immunotherapy Targeting IDO Mediated Immune Suppression

Amobi, A. E., Qian, F., Lugade, A. A., & Odunsi, K. O. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-67577-0_9 · Cited by 88 · see citing works

CD200-CD200R signaling suppresses anti-tumor responses independently of CD200 expression on the tumor

Rygiel, T. P., Karnam, G., Goverse, G., van der Marel, A. P. J., Greuter, M., van Schaarenburg, R. A., Visser, W. F., Brenkman, A. B., Molenaar, R., Hoek, R. M., et al. (2011) · Oncogene · doi:10.1038/onc.2011.477 · Cited by 80 · see citing works

BRAF inhibition improves tumor recognition by the immune system

Donia, M., Fagone, P., Nicoletti, F., Andersen, R. S., Høgdall, E. V. S., Straten, P. T., Andersen, M. H., & Svane, I. M. (2012) · OncoImmunology · doi:10.4161/onci.21940 · Cited by 78 · see citing works

Lung adenocarcinoma-intrinsic GBE1 signaling inhibits anti-tumor immunity

Li, L., Li, Y., Cheng, S., Fan, Z., Shen, Z., Xue, W., Zheng, Y., Li, F., Wang, D., Zhang, K., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1027-x · Cited by 76 · see citing works

Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor

Nishio, H., Yaguchi, T., Sugiyama, J., Sumimoto, H., Umezawa, K., Iwata, T., Susumu, N., Fujii, T., Kawamura, N., Kobayashi, A., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.251 · Cited by 74 · see citing works

Stattic and metformin inhibit brain tumor initiating cells by reducing STAT3-phosphorylation

Leidgens, V., Proske, J., Rauer, L., Moeckel, S., Renner, K., Bogdahn, U., Riemenschneider, M. J., Proescholdt, M. A., Vollmann‐Zwerenz, A., Hau, P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14159 · Cited by 72 · see citing works

Trp53 Inactivation in the Tumor Microenvironment Promotes Tumor Progression by Expanding the Immunosuppressive Lymphoid-like Stromal Network

Guo, G., Marrero, L., Rodrı́guez, P. C., Valle, L. D., Ochoa, A. C., & Cui, Y. R. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3810 · Cited by 69 · see citing works

TTK Inhibitors as a Targeted Therapy for CTNNB1 ( β -catenin) Mutant Cancers

Zaman, G. J. R., de Roos, J. A. D. M., Libouban, M. A. A., Prinsen, M. B. W., de Man, J., Buijsman, R. C., & Uitdehaag, J. C. M. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0342 · Cited by 64 · see citing works

Co-delivery of DOX and PDTC by pH-sensitive nanoparticles to overcome multidrug resistance in breast cancer

Cheng, X., Li, D., Sun, M., He, L., Zheng, Y., Wang, X., & Tang, R. (2019) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2019.05.042 · Cited by 63 · see citing works

TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs

Won, H., Moreira, D., Gao, C., Duttagupta, P. A., Zhao, X., Manuel, E. R., Diamond, D. J., Yuan, Y., Liu, Z., Jones, J. O., et al. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.3ma1016-451rr · Cited by 62 · see citing works

Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53

Quigley, D. A., Silwal‐Pandit, L., Dannenfelser, R., Langerød, A., Vollan, H. K. M., Vaske, C. J., Siegel, J. U., Troyanskaya, O. G., Chin, S., Caldas, C., et al. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0387 · Cited by 61 · see citing works

The Receptor for Advanced Glycation End Products Promotes Pancreatic Carcinogenesis and Accumulation of Myeloid-Derived Suppressor Cells

Vernon, P. J., Loux, T., Schapiro, N. E., Kang, R., Muthuswamy, R., Kaliński, P., Tang, D., Lotze, M. T., & Zeh, H. J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201151 · Cited by 57 · see citing works

Inhibitory roles of signal transducer and activator of transcription 3 in antitumor immunity during carcinogen-induced lung tumorigenesis.

Ihara, S., Kida, H., Arase, H., Tripathi, L., Chen, Y.-A., Kimura, T., Yoshida, M., Kashiwa, Y., Hirata, H., Fukamizu, R., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4062 · Cited by 56 · see citing works

Rapamycin suppresses TLR4-triggered IL-6 and PGE2 production of colon cancer cells by inhibiting TLR4 expression and NF-κB activation

Sun, Q., Liu, Q., Zheng, Y., & Cao, X. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.01.025 · Cited by 55 · see citing works

Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial

Uppaluri, R., Winkler, A. E., Lin, T., Law, J. H., Haughey, B. H., Nussenbaum, B. A., Paniello, R. C., Rich, J. T., Diaz, J. A., Michel, L., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1469 · Cited by 53 · see citing works

Targeting Stat3 Induces Senescence in Tumor Cells and Elicits Prophylactic and Therapeutic Immune Responses against Breast Cancer Growth Mediated by NK Cells and CD4+ T Cells

Tkach, M., Coria, L. M., Rosemblit, C., Rivas, M. A., Proietti, C. J., Flaqué, M. C. D., Béguelin, W., Frahm, I., Charreau, E. H., Cassataro, J., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102538 · Cited by 50 · see citing works

Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms' Tumor

Maturu, P., Jones, D. E., Ruteshouser, E., Hu, Q.-H., Reynolds, J., Hicks, J., Putluri, N., Ekmekcioglu, S., Grimm, E., Chen, D., et al. (2017) · Neoplasia · doi:10.1016/j.neo.2016.07.009 · Cited by 47 · see citing works

Impact of MAPK Pathway Activation in BRAFV600 Melanoma on T Cell and Dendritic Cell Function

Ott, P. A., & Bhardwaj, N. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00346 · Cited by 41 · see citing works

Induction of PD-L1 expression by epidermal growth factor receptor–mediated signaling in esophageal squamous cell carcinoma

Zhang, W., Pang, Q., Yan, C., Wang, Q., Yang, J., Yu, S., Liu, X., Yuan, Z., Wang, P., & Xiao, Z. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s118982 · Cited by 41 · see citing works

The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo

Shi, F., Zhang, J., Liu, H., Wu, L., Jiang, H., Wu, Q., Liu, T., Lou, M., & Wu, H. (2017) · Oncotarget · doi:10.18632/oncotarget.23091 · Cited by 41 · see citing works

Modeling synovial sarcoma metastasis in the mouse: PI3′-lipid signaling and inflammation

Barrott, J. J., Kafchinski, L. A., Jin, H., Potter, J. W., Kannan, S., Kennedy, R., Mosbruger, T., Wang, W., Tsai, J.-W., Araujo, D. M., et al. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20160817 · Cited by 37 · see citing works

The Dual PI3K/mToR Inhibitor Omipalisib/GSK2126458 Inhibits Clonogenic Growth in Oncogenically-transformed Cells from Neurocutaneous Melanocytosis

Basu, D., Salgado, C. M., Bauer, B. S., Khakoo, Y., Patel, J. R., Hoehl, R. M., Bertolini, D. M., Zabec, J., Brzozowski, M., & Reyes‐Múgica, M. (2018) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20082 · Cited by 26 · see citing works

Signal Transducer and Activator of Transcription 1 Plays a Pivotal Role in RET/PTC3 Oncogene-induced Expression of Indoleamine 2,3-Dioxygenase 1

Moretti, S., Menicali, E., Nucci, N., Voce, P., Colella, R., Melillo, R. M., Liotti, F., Morelli, S., Fallarino, F., Macchiarulo, A., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.745448 · Cited by 24 · see citing works

Akti-1/2, an allosteric inhibitor of Akt 1 and 2, efficiently inhibits CaMKIα activity and aryl hydrocarbon receptor pathway

Gilot, D., Giudicelli, F., Lagadic‐Gossmann, D., & Fardel, O. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.08.011 · Cited by 22 · see citing works

The NFκB inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype

Zhang, L., Ren, X., Cheng, Y., Liu, X., Allen, J. E., Zhang, Y., Yuan, Y., Huang, S.-Y., Yang, W., Berg, A. S., et al. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.28158 · Cited by 17 · see citing works

Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non–Small-Cell Lung Cancer: Findings From a Real-Life Cohort

Dudnik, E., Bar, J., Peled, N., Bshara, E., Kuznetsov, T., Cohen, A. Y., Shochat, T., Nechushtan, H., Onn, A., Agbarya, A., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.03.007 · Cited by 15 · see citing works

Indoximod Combo Triggers Responses in Melanoma

(2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2017-056 · Cited by 9 · see citing works

Combinatory effects of vaccinia virus VG9 and the STAT3 inhibitor Stattic on cancer therapy

Yang, R.-L., Wang, L.-Z., Sheng, J., Huang, Q., Pan, D., Xu, Y.-P., Yan, J.-J., Wang, X.-Y., Dong, Z., & Yang, M. (2019) · Archives of Virology · doi:10.1007/s00705-019-04257-2 · Cited by 7 · see citing works

VEGFR2-targeted fusion antibody improved NK cell-mediated immunosurveillance against K562 cells

Ren, X., Xie, W., Wang, Y., Xu, M., Liu, F., Tang, M., Li, C., Wang, M., & Zhang, J. (2016) · Immunologic Research · doi:10.1007/s12026-016-8800-3 · Cited by 4 · see citing works

Roles of IFN-γ in tumor progression and regression: A review

Jorgovanovic, D., Song, M., Wang, L., & Zhang, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-00228-x · Cited by 1,234 · see citing works

Cancer vaccines as promising immuno-therapeutics: platforms and current progress

Liu, J., Fu, M., Wang, M., Wan, D., Wei, Y., & Wei, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01247-x · Cited by 725 · see citing works

Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy

Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546 · see citing works

Immunosenescence: a key player in cancer development

Lian, J., Yue, Y., Yu, W., & Zhang, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00986-z · Cited by 510 · see citing works

Exosome-based immunotherapy: a promising approach for cancer treatment

Xu, Z., Zeng, S., Gong, Z., & Yan, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01278-3 · Cited by 510 · see citing works

Role of tumor microenvironment in cancer progression and therapeutic strategy

Wang, Q., Shao, X., Zhang, Y., Zhu, M., Wang, F. X. C., Mu, J., Li, J., Yao, H., & Chen, K. (2023) · Cancer Medicine · doi:10.1002/cam4.5698 · Cited by 462 · see citing works

Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors

Lei, Q., Wang, D., Sun, K., Wang, L., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00672 · Cited by 414 · see citing works

Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity

Duong, E., Fessenden, T. B., Lutz, E., Dinter, T., Yim, L., Blatt, S., Bhutkar, A., Wittrup, K. D., & Spranger, S. (2022) · Immunity · doi:10.1016/j.immuni.2021.10.020 · Cited by 372 · see citing works

Mechanisms driving the immunoregulatory function of cancer cells

van Weverwijk, A., & de Visser, K. E. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-022-00544-4 · Cited by 279 · see citing works

Contradictory roles of lipid metabolism in immune response within the tumor microenvironment

Yu, W., Lei, Q., Yang, L., Qin, G., Liu, S., Wang, D., Ping, Y., & Zhang, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01200-4 · Cited by 272 · see citing works

Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy

Mirlekar, B. (2022) · SAGE Open Medicine · doi:10.1177/20503121211069012 · Cited by 261 · see citing works

Gene modification strategies for next-generation CAR T cells against solid cancers

Tian, Y., Li, Y., Shao, Y., & Zhang, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00890-6 · Cited by 177 · see citing works

Immunosenescence, Inflammaging, and Frailty: Role of Myeloid Cells in Age-Related Diseases

Bleve, A., Motta, F., Durante, B., Pandolfo, C., Selmi, C., & Sica, A. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08909-7 · Cited by 179 · see citing works

Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges

Xiang, Y., Liu, X., Wang, Y., Zheng, D., Meng, Q., Jiang, L., Yang, S., Zhang, S., Zhang, X., Liu, Y., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1366260 · Cited by 146 · see citing works

Metabolic Modulation of the Tumor Microenvironment Leads to Multiple Checkpoint Inhibition and Immune Cell Infiltration

Kolb, D., Kolishetti, N., Surnar, B., Sarkar, S., Guin, S., Shah, A. S., & Dhar, S. (2020) · ACS Nano · doi:10.1021/acsnano.9b10037 · Cited by 137 · see citing works

Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients

Kumar, S., Chatterjee, M., Ghosh, P., Ganguly, K. K., Basu, M., & Ghosh, M. K. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.07.024 · Cited by 132 · see citing works

The impact of lipid metabolism on breast cancer: a review about its role in tumorigenesis and immune escape

dos Santos, D. Z., de Souza, J. C., Pimenta, T. M., Martins, B. D. S., Ribeiro, R. S., Butzene, S. M. S., Tessarolo, N. G., Junior, P. C. M. L., Silva, I. V., & Rangel, L. B. A. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01178-1 · Cited by 131 · see citing works

Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy

Morelli, T., Fujita, K., Redelman‐Sidi, G., & Elkington, P. T. (2021) · Thorax · doi:10.1136/thoraxjnl-2021-217260 · Cited by 116 · see citing works

Engineering lactate-modulating nanomedicines for cancer therapy

Chen, J., Zhu, Y., Wu, C., & Shi, J. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00479h · Cited by 106 · see citing works

Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis

Shabaneh, T. B., Molodtsov, A. K., Steinberg, S. M., Zhang, P., Torres, G. M., Mohamed, G. A., Boni, A., Curiel, T. J., Angeles, C. V., & Turk, M. J. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0365 · Cited by 103 · see citing works

Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade

Lei, Y., Li, X., Huang, Q., Zheng, X., & Liu, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.617335 · Cited by 91 · see citing works

Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance

Hossain, S. M., & Eccles, M. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021601 · Cited by 89 · see citing works

UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced PDL1 transcription in triple negative breast cancer

Wu, B., Song, M. L., Dong, Q., Xiang, G., Li, J., Ma, X., & Wei, F. (2022) · Theranostics · doi:10.7150/thno.74989 · Cited by 87 · see citing works

CAR-T Cell Therapy—An Overview of Targets in Gastric Cancer

Bębnowska, D., Grywalska, E., Niedźwiedzka‐Rystwej, P., Sosnowska‐Pasiarska, B., Smok-Kalwat, J., Pasiarski, M., Góźdź, S. S., Roliński, J., & Polkowski, W. P. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061894 · Cited by 86 · see citing works

KRT17 Promotes T-lymphocyte Infiltration Through the YTHDF2–CXCL10 Axis in Colorectal Cancer

Liang, W., Liu, H., Zeng, Z., Liang, Z., Xie, H., Li, W., Xiong, L., Liu, Z., Chen, M., Jie, H., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0814 · Cited by 81 · see citing works

mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model

Sittplangkoon, C., Alameh, M.-G., Weissman, D., Lin, P. J. C., Tam, Y. K., Prompetchara, E., & Palaga, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.983000 · Cited by 79 · see citing works

Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer

Chen, X., Feng, L., Huang, Y., Wu, Y., & Xie, N. (2022) · Cancers · doi:10.3390/cancers15010104 · Cited by 81 · see citing works

Interrelation between Programmed Cell Death and Immunogenic Cell Death: Take Antitumor Nanodrug as an Example

Meng, Q., Ding, B., Ma, P., & Lin, J. (2023) · Small Methods · doi:10.1002/smtd.202201406 · Cited by 74 · see citing works

Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy

Czajka‐Francuz, P., Prendes, M. J., Mankan, A. K., Quintana, Á., Pabla, S., Ramkissoon, S. H., Jensen, T. J., Peiró, S., Severson, E. A., Achyut, B. R., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1200646 · Cited by 69 · see citing works

Metabolic reprogramming in the immunosuppression of tumor-associated macrophages

Wang, Y., Wang, D., Yang, L., & Zhang, Y. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002426 · Cited by 66 · see citing works

Implantable and Injectable Biomaterial Scaffolds for Cancer Immunotherapy

Li, J., Luo, Y., Li, B., Xia, Y., Wang, H., & Fu, C. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.612950 · Cited by 64 · see citing works

Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis

Xing, X., Shi, J., Jia, Y., Dou, Y., Li, Z., Dong, B., Guo, T., Cheng, X., Li, X., Du, H., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003984 · Cited by 62 · see citing works

In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response

Sahu, A., Köse, K., Kraehenbuehl, L., Byers, C., Holland, A., Tembo, T., Santella, A., Alfonso, A., Li, M., Cordova, M. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32738-7 · Cited by 62 · see citing works

IL‐33/ST2 as a potential target for tumor immunotherapy

Jiang, W., Lian, J., Yue, Y., & Zhang, Y. (2021) · European Journal of Immunology · doi:10.1002/eji.202149175 · Cited by 58 · see citing works

Research progress on the immune microenvironment and immunotherapy in gastric cancer

Mou, P., Ge, Q., Sheng, R., Zhu, T.-F., Liu, Y., & Ding, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1291117 · Cited by 58 · see citing works

Increased Nuclear Transporter KPNA2 Contributes to Tumor Immune Evasion by Enhancing PD-L1 Expression in PDAC

Zhou, K., Huang, S., Hu, L.-P., Zhang, X., Qin, W., Zhang, Y., Yao, L.-L., Yu, Y., Zhou, Y.-Q., Zhu, L., et al. (2021) · Journal of Immunology Research · doi:10.1155/2021/6694392 · Cited by 55 · see citing works

Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy

Moon, Y., Jeon, S. I., Shim, M. K., & Kim, K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020411 · Cited by 55 · see citing works

Augmenting the Effectiveness of CAR-T Cells by Enhanced Self-Delivery of PD-1-Neutralizing scFv

Yü, P., Li, F., Nan, S., Zhang, D., Shi, X., Shan, J., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00803 · Cited by 51 · see citing works

The functions and regulation of Otubains in protein homeostasis and diseases

Zhu, Q., Fu, Y., Li, L., Liu, C. H., & Zhang, L. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101303 · Cited by 46 · see citing works

Targeting metabolic reprogramming in chronic lymphocytic leukemia

Nie, Y., Yun, X., Zhang, Y., & Wang, X. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00292-z · Cited by 45 · see citing works

The tumor immune microenvironment: implications for cancer immunotherapy, treatment strategies, and monitoring approaches

Racacho, K. J., Shiau, Y., Villa, R., Mahri, S., Tang, M., Lin, T., & Li, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1621812 · Cited by 54 · see citing works

Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors

Olbryt, M., Rajczykowski, M., & Widłak, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114071 · Cited by 42 · see citing works

Nanoparticle-Based Therapies for Turning Cold Tumors Hot: How to Treat an Immunosuppressive Tumor Microenvironment

Giustarini, G., Pavesi, A., & Adriani, G. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.689245 · Cited by 42 · see citing works

FGFR1/MAPK-directed brachyury activation drives PD-L1-mediated immune evasion to promote lung cancer progression

Hu, Y., Lu, Y. C., Xing, F., & Hsu, W. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215867 · Cited by 40 · see citing works

Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer

Bueschbell, B., Caniceiro, A. B., Suzano, P. M. S., Machuqueiro, M., Rosário‐Ferreira, N., & Moreira, I. S. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100811 · Cited by 37 · see citing works

Tumor-intrinsic IRE1α signaling controls protective immunity in lung cancer

Crowley, M. J. P., Bhinder, B., Markowitz, G. J., Martin, M. T., Verma, A., Sandoval, T. A., Chae, C.-S., Yomtoubian, S., Hu, Y., Chopra, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35584-9 · Cited by 37 · see citing works

Cancer Resistance to Immunotherapy: Molecular Mechanisms and Tackling Strategies

Vu, S. H., Vetrivel, P., Kim, J., & Lee, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810906 · Cited by 36 · see citing works

Impact of immunosenescence and inflammaging on the effects of immune checkpoint inhibitors

Hou, C., Wang, Z., & Lu, X. (2023) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2023.08.001 · Cited by 37 · see citing works

Self‐Carrier Nanoparticles for Delivery of Paclitaxel and IDO Inhibitor to Boost Antitumor Chemo‐Immunotherapy

Li, Z., Pei, Q., Zhao, M., Xie, Z., & Zheng, M. J. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202312500 · Cited by 36 · see citing works

Regulation of aromatase in cancer

Molehin, D., Rasha, F. A., Rahman, R. L., & Pruitt, K. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04099-0 · Cited by 36 · see citing works

Immunosenescence and cancer: Opportunities and challenges

Fu, Z., Xu, H., Yue, L., Zheng, W., Pan, L., Gao, F., & Liu, X. (2023) · Medicine · doi:10.1097/md.0000000000036045 · Cited by 36 · see citing works

Association of IDH mutation and 1p19q co-deletion with tumor immune microenvironment in lower-grade glioma

Lin, W., Qiu, X., Sun, P., Ye, Y., Huang, Q., Kong, L., & Lu, J. J. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.04.010 · Cited by 35 · see citing works

A2AR-mediated CXCL5 upregulation on macrophages promotes NSCLC progression via NETosis

Lei, Q., Zhen, S., Zhang, L., Zhao, Q., Li, Y., & Zhang, Y. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03689-3 · Cited by 30 · see citing works

Decoding Strategies to Evade Immunoregulators Galectin-1, -3, and -9 and Their Ligands as Novel Therapeutics in Cancer Immunotherapy

Lau, L. S., Mohammed, N. B. B., & Dimitroff, C. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415554 · Cited by 29 · see citing works

A nanoformulation for immunosuppression reversal and broad-spectrum self-amplifying antitumor ferroptosis-immunotherapy

Yang, Q., Liu, T., Zheng, H., Zhou, Z., Huang, Y., Jia, H., Fu, S., Zhang, X., Zhang, H., Liu, Y., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121936 · Cited by 29 · see citing works

MicroRNAs as Emerging Regulators of Signaling in the Tumor Microenvironment

Syed, S. N., & Brüne, B. (2020) · Cancers · doi:10.3390/cancers12040911 · Cited by 28 · see citing works

Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy

Kortekaas, K. E., Santegoets, S. J. A. M., Tas, L., Ehsan, I., Charoentong, P., van Doorn, H. C., van Poelgeest, M. I. E., Mustafa, D. A. M., & van der Burg, S. H. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003671 · Cited by 28 · see citing works

TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Lin, A., Zhang, H., Meng, H., Deng, Z., Gu, T., Luo, P., & Zhang, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.667875 · Cited by 27 · see citing works

MTAP deficiency contributes to immune landscape remodelling and tumour evasion

Chang, W., Hsu, S., Zhang, J., Li, J., Yang, D. C. H., Chu, C., Yoo, E. H., Zhang, W., Yu, S., & Chen, C. (2022) · Immunology · doi:10.1111/imm.13587 · Cited by 29 · see citing works

Decreased m6A Modification of CD34/CD276(B7-H3) Leads to Immune Escape in Colon Cancer

Zhou, Y., Zhou, H., Shi, J., Guan, A., Zhu, Y., Hou, Z., & Li, R. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.715674 · Cited by 26 · see citing works

Hybrid Cell Membrane‐Based Nanoplatforms for Enhanced Immunotherapy against Cancer and Infectious Diseases

Peng, X., Li, Y., Yuan, P., & Ding, X. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304477 · Cited by 27 · see citing works

PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6high uterine leiomyosarcoma to PD‐1 blockade

Wispelaere, W. D., Annibali, D., Tuyaerts, S., Messiaen, J., Antoranz, A., Shankar, G., Dubroja, N., Herreros‐Pomares, A., Baiden-Amissah, R. E. M., Orban, M., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1655 · Cited by 24 · see citing works

L1CAM Overexpression Promotes Tumor Progression Through Recruitment of Regulatory T Cells in Esophageal Carcinoma

Zhao, X., Liu, S., Chen, X., Zhao, J., Li, F., Zhao, Q., Xie, T., Huang, L., Zhang, Z., Qi, Y., et al. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0182 · Cited by 25 · see citing works

Cellular Immunotherapy in Gastric Cancer: Adoptive Cell Therapy and Dendritic Cell-Based Vaccination

Faghfuri, E., Shadbad, M. A., Faghfouri, A. H., & Soozangar, N. (2022) · Immunotherapy · doi:10.2217/imt-2021-0285 · Cited by 25 · see citing works

Targeting immunosenescence for improved tumor immunotherapy

Liu, Z., Zuo, L., Zhou, Z., Liu, S., Ba, Y., Zuo, A., Ren, Y., Zhang, C., Chen, Y., Ma, H., et al. (2024) · MedComm · doi:10.1002/mco2.777 · Cited by 24 · see citing works

Single‐cell RNA sequencing reveals localized tumour ablation and intratumoural immunostimulant delivery potentiate T cell mediated tumour killing

Hoover, A. R., Liu, K., DeVette, C. I., Krawic, J. R., Medcalf, A. D., West, C. L., Hode, T., Lam, S. S. K., Welm, A. L., Sun, X., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.937 · Cited by 24 · see citing works

Comprehensive Analysis of the Tumor Microenvironment in Cutaneous Melanoma associated with Immune Infiltration

Wang, P., Zhang, X., Sun, N., Zhao, Z., & He, J. (2020) · Journal of Cancer · doi:10.7150/jca.44413 · Cited by 24 · see citing works

Bojungikki-Tang Improves Response to PD-L1 Immunotherapy by Regulating the Tumor Microenvironment in MC38 Tumor-Bearing Mice

Chun, J., Park, S., Yi, J.-M., Ha, I. J., Kang, H. N., & Jeong, M.-K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.901563 · Cited by 23 · see citing works

Proteomics and liquid biopsy characterization of human EMT-related metastasis in colorectal cancer

Huang, M., Fu, L., Yan, H., Cheng, L.-Y., Ru, H., Mo, S., Wei, C., Li, D.-M., Mo, X., Tang, W., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.790096 · Cited by 23 · see citing works

The role of tumor necrosis factor receptor superfamily in cancer: insights into oncogenesis, progression, and therapeutic strategies

Xu, J. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00990-x · Cited by 24 · see citing works

Intravenous delivery of STING agonists using acid-sensitive polycationic polymer-modified lipid nanoparticles for enhanced tumor immunotherapy

He, Y., Zheng, K., Qin, X., Wang, S., Li, X., Liu, H., Liu, M., Xu, R., Peng, S., & Pang, Z. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.06.004 · Cited by 19 · see citing works

Immune Modulation and Immunotherapy in Solid Tumors: Mechanisms of Resistance and Potential Therapeutic Strategies

Giri, S., Lamichhane, G., Pandey, J., Khadayat, R., Sindhu, K. C., Devkota, H. P., & Khadka, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26072923 · Cited by 19 · see citing works

Monitoring Extracellular Ion and Metabolite Dynamics with Recombinant Nanobody-Fused Biosensors

Burgstaller, S., Wagner, T. R., Bischof, H., Bueckle, S., Padamsey, A., Frecot, D. I., Kaiser, P. D., Skrabak, D., Malli, R., Łukowski, R., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104907 · Cited by 19 · see citing works

Precise delivery of doxorubicin and imiquimod through pH-responsive tumor microenvironment-active targeting micelles for chemo- and immunotherapy

Wen, Y.-H., Hsieh, P.-I., Chiu, H., Chiang, C.-W., Lo, C.-L., & Chiang, Y. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100482 · Cited by 19 · see citing works

Tackling of Immunorefractory Tumors by Targeting Alternative Immune Checkpoints

Dulal, D., Boring, A. R., Terrero, D., Johnson, T. L., Tiwari, A. K., & Raman, D. (2023) · Cancers · doi:10.3390/cancers15102774 · Cited by 18 · see citing works

Adoptive CD8 + T-cell grafted with liposomal immunotherapy drugs to counteract the immune suppressive tumor microenvironment and enhance therapy for melanoma

Liu, S., Liu, H., Song, X., Jiang, A., Deng, Y., Yang, C., Sun, D., Jiang, K., Yang, F., & Zheng, Y. (2021) · Nanoscale · doi:10.1039/d1nr04036g · Cited by 18 · see citing works

Nano-sized drug delivery systems to potentiate the immune checkpoint blockade therapy

Shim, M. K., Song, S. K., Jeon, S. I., Hwang, K. Y., & Kim, K. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2081683 · Cited by 18 · see citing works

The DARC Side of Inflamm-Aging: Duffy Antigen Receptor for Chemokines (DARC/ACKR1) as a Potential Biomarker of Aging, Immunosenescence, and Breast Oncogenesis among High-Risk Subpopulations

Jinna, N., Rida, P. C. G., Su, T., Gong, Z., Yao, S., LaBarge, M. A., Natarajan, R. D., Jovanović‐Talisman, T., Ambrosone, C. B., & Seewaldt, V. L. (2022) · Cells · doi:10.3390/cells11233818 · Cited by 18 · see citing works

Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types

Guo, B., Wang, Y., Liu, W., & Zhang, S. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02968-8 · Cited by 17 · see citing works

The Prognosis of Cancer Depends on the Interplay of Autophagy, Apoptosis, and Anoikis within the Tumor Microenvironment

Gulia, S., Chandra, P., & Das, A. (2023) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-023-01179-4 · Cited by 16 · see citing works

Identification of a Prognostic Immune Signature for Esophageal Squamous Cell Carcinoma to Predict Survival and Inflammatory Landscapes

Zhang, C., Luo, Y., Zhang, Z., Zhang, Z., Zhang, G., Wang, F., Che, Y., Fang, L., Zhang, Y., Sun, N., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.580005 · Cited by 16 · see citing works

Plasmacytoid Dendritic Cells in Patients with MGUS and Multiple Myeloma

Knight, A., Říhová, L., Králová, R., Penka, M., Adam, Z., Pour, L., Piskáček, M., & Hájek, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10163717 · Cited by 15 · see citing works

Identification of a ceRNA Network in Lung Adenocarcinoma Based on Integration Analysis of Tumor-Associated Macrophage Signature Genes

Zhang, L., Zhang, K., Liu, S., Zhang, R., Yang, Y., Wang, Q., Zhao, S., Li, Y., Zhang, Y., & Wang, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.629941 · Cited by 15 · see citing works

Highlights of Immunomodulation in Salmonella-Based Cancer Therapy

Pangilinan, C., & Lee, C.-H. (2021) · Biomedicines · doi:10.3390/biomedicines9111566 · Cited by 12 · see citing works

Hereditary Diffuse Gastric Cancer: A 2022 Update

Kole, C., Charalampakis, N., Sakellariou, S., Papaxoinis, G., Apostolou, K. G., Machairas, N., Papanikolaou, I. S., & Schizas, D. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12122032 · Cited by 14 · see citing works

Nanocarrier-based drug delivery via cell-hitchhiking: Emphasizing pharmacokinetic perspective towards taming the “big-old” tumors

Famta, P., Shah, S., Jain, N., Srinivasarao, D. A., Vambhurkar, G. B., Shahrukh, S., Murthy, A. N., Ahmed, T., Pandey, G., Sharma, A., et al. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105050 · Cited by 14 · see citing works

Stromal senescence contributes to age-related increases in cancer

Ye, J., Melam, A., & Stewart, S. A. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00840-9 · Cited by 14 · see citing works

HydrAd: A Helper-Dependent Adenovirus Targeting Multiple Immune Pathways for Cancer Immunotherapy

Shaw, A. R., Porter, C. E., Biegert, G. W. G., Jatta, L., & Suzuki, M. (2022) · Cancers · doi:10.3390/cancers14112769 · Cited by 13 · see citing works

From single gene analysis to single cell profiling: a new era for precision medicine

Martino, M. T. D., Meschini, S., Scotlandi, K., Riganti, C., Smaele, E. D., Zazzeroni, F., Donadelli, M., Leonetti, C., & Caraglia, M. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01549-3 · Cited by 13 · see citing works

Beyond CAR T cells: Engineered Vγ9Vδ2 T cells to fight solid tumors

Rafia, C., Harly, C., & Scotet, E. (2020) · Immunological Reviews · doi:10.1111/imr.12920 · Cited by 13 · see citing works

Efferocytosis in Health and Disease

Li, C., Yang, Y., Zhou, F., Jiang, Q., Jiang, Y., Huang, X., Zhang, Y., Ye, Z., Xu, G. X., Kao, G., et al. (2025) · MedComm · doi:10.1002/mco2.70546 · Cited by 15 · see citing works

A glioneuronal tumor with CLIP2-MET fusion

Chowdhury, T., Lee, Y., Kim, S., Yu, H. J., Ji, S. Y., Bae, J. M., Won, J., Shin, J. H., Weinberger, D. R., Choi, S. H., et al. (2020) · npj Genomic Medicine · doi:10.1038/s41525-020-0131-6 · Cited by 12 · see citing works

The combination of novel immune checkpoints HHLA2 and ICOSLG: A new system to predict survival and immune features in esophageal squamous cell carcinoma

Zhang, C., Wang, F., Sun, N., Zhang, Z., Zhang, G., Zhang, Z., Luo, Y., Che, Y., Cheng, H., Li, J., et al. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.08.003 · Cited by 12 · see citing works

CXCL10-coronated thermosensitive “stealth” liposomes for sequential chemoimmunotherapy in melanoma

Xin, X., Zhou, Y., Li, J., Zhang, K., Qin, C., & Yin, L. (2022) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2022.102634 · Cited by 12 · see citing works

Identification and characterization of prognosis-related genes in the tumor microenvironment of esophageal squamous cell carcinoma

Qu, J., Zhao, Q., Yang, L., Ping, Y., Zhang, K., Lei, Q., Liu, F., & Zhang, Y. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107616 · Cited by 12 · see citing works

Epigenetic modulation of immune cells: Mechanisms and implications

Fiordoro, S., Rosano, C., Pechkova, E., Barocci, S., & Izzotti, A. (2024) · Advances in Biological Regulation · doi:10.1016/j.jbior.2024.101043 · Cited by 11 · see citing works

Emerging Immunotherapy Targets in Early Drug Development

Araujo, D. M., Catani, G., Mirallas, O., Pretelli, G., Sánchez-Pérez, V., Vieito, M., Braña, I., Pujol‐Borrell, R., Garralda, E., & Hernando‐Calvo, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115394 · Cited by 11 · see citing works

Exploring therapeutic targets and drug candidates for obesity: a combined network pharmacology, bioinformatics approach

Aloufi, B. H., Alshabrmi, F. M., Sreeharsha, N., & Rehman, A. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2265491 · Cited by 11 · see citing works

Targeting oncogenic signal pathway to improve cancer immunotherapy: Insights and perspectives

Yang, Q., Sun, H., & Sun, Z. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117043 · Cited by 10 · see citing works

SIGNALING PATHWAYS IN IMMUNOTHERAPY

Güneş, B. A., & Özkan, T. (2025) · Turkiye Klinikleri eBooks · doi:10.5336/978-625-395-657-8_p65

Tumor-intrinsic oncogene pathways mediating immune avoidance

Spranger, S., & Gajewski, T. F. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1086862 · Cited by 146 · see citing works

Metabolically targeting immunosuppression and immunoescape for future cancer immunotherapy: a narrative review

Huang, B., & Cao, X. (2022) · Holistic Integrative Oncology · doi:10.1007/s44178-022-00018-5 · Cited by 16 · see citing works

From intracellular drivers to immune modulators: emerging paradigms in oncogenic pathway-directed immunotherapy optimization

Rao, D., Wang, T., Fu, C., Luo, Y., Lu, J., Sun, Z., Yan, W., Liang, H., Xia, L., & Huang, W. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02465-9 · Cited by 6 · see citing works

The non-T-cell-inflamed tumor microenvironment: contributing factors and therapeutic solutions

Horton, B. L., & Spranger, S. (2017) · Emerging Topics in Life Sciences · doi:10.1042/etls20170073 · Cited by 5 · see citing works